home · filing · 0001193125-21-291534
8-K filed October 5, 2021, 7:59 PM ET
ticker FNCHQ
CIK 0001733257
leadership
confidence high
sentiment neutral
materiality 0.30
Finch Therapeutics appoints Samuel Allen Hamood to Board of Directors
Finch Therapeutics Group, Inc.
Hamood elected as Class I director effective Oct 1, 2021; also chairs new Finance Committee.
Annual cash retainers: $35,000 for Board, $5,000 for Finance Committee, $10,000 as chair.
Initial equity grant: option to buy 25,543 shares at $12.94, $200,000 fair value, 3-year vest.
Hamood serves as President and CAFO of Culligan International; 30+ years of finance experience.
Board determined Hamood qualifies as independent under SEC and Nasdaq standards.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2021-10-01
Filed October 5, 2021, 7:59 PM ET
elected Samuel Allen Hamood to the Board, effective immediately, to serve as a Class I director
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Samuel Allen Hamood was elected as Director at Finch Therapeutics Group, Inc..
Action elected
Role Director
Exact text from the filing
elected Samuel Allen Hamood to the Board, effective immediately, to serve as a Class I director
View on SEC.gov
Source: SEC EDGAR
accession 0001193125-21-291534
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.